基于Sm-p80的DNA疫苗制剂可诱导针对曼氏血吸虫的强效保护性免疫。
Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni.
作者信息
Ahmad G, Torben W, Zhang W, Wyatt M, Siddiqui A A
机构信息
Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, Lubbock, 79430, USA.
出版信息
Parasite Immunol. 2009 Mar;31(3):156-61. doi: 10.1111/j.1365-3024.2008.01091.x.
Abstract
No effective vaccine exists for the human parasitic disease, schistosomiasis. We have targeted a functionally important antigen, Sm-p80 as a vaccine candidate because of its consistent immunogenicity, protective potential and important role in the immune evasion process. In this study we report that a Sm-p80-based DNA vaccine formulation confers 59% reduction in worm burden in mice. Animals immunized with Sm-p80-pcDNA3 exhibited a decrease in egg production by 84%. Sm-p80 DNA elicited strong immune responses that include IgG2A and IgG2B antibody isotypes in vaccinated animals. Splenocytes proliferated in response to Sm-p80 produced appreciably more Th1 response enhancing cytokines (IL-2, IFN-gamma) than Th2 response enhancing cytokines (IL-4, IL-10). These data reinforce the potential of Sm-p80 as an excellent vaccine candidate for schistosomiasis.
摘要
目前尚无针对人类寄生虫病血吸虫病的有效疫苗。我们已将一种功能重要的抗原Sm-p80作为疫苗候选物，因为它具有一致的免疫原性、保护潜力以及在免疫逃避过程中的重要作用。在本研究中，我们报告基于Sm-p80的DNA疫苗制剂可使小鼠体内的虫负荷降低59%。用Sm-p80-pcDNA3免疫的动物产卵量减少了84%。Sm-p80 DNA在接种动物中引发了强烈的免疫反应，包括IgG2A和IgG2B抗体亚型。脾细胞对Sm-p80产生增殖反应，产生的增强Th1反应的细胞因子（IL-2、IFN-γ）明显多于增强Th2反应的细胞因子（IL-4、IL-10）。这些数据强化了Sm-p80作为血吸虫病优秀疫苗候选物的潜力。
相似文献
1
Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni.
Parasite Immunol. 2009 Mar;31(3):156-61. doi: 10.1111/j.1365-3024.2008.01091.x.
2
Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine.
J Infect Dis. 2010 Apr 1;201(7):1105-12. doi: 10.1086/651147.
3
Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model.
Vaccine. 2009 May 11;27(21):2830-7. doi: 10.1016/j.vaccine.2009.02.096. Epub 2009 Mar 10.
4
Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine.
Parasitol Res. 2009 Nov;105(6):1767-77. doi: 10.1007/s00436-009-1646-z. Epub 2009 Oct 7.
5
Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse.
Parasite Immunol. 2010 Apr;32(4):252-8. doi: 10.1111/j.1365-3024.2009.01181.x.
6
Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice.
Int J Infect Dis. 2010 Sep;14(9):e781-7. doi: 10.1016/j.ijid.2010.02.2266. Epub 2010 Jul 13.
7
Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium.
Parasitol Res. 2017 Nov;116(11):3175-3188. doi: 10.1007/s00436-017-5634-4. Epub 2017 Oct 12.
8
Role of antibodies in Sm-p80-mediated protection against Schistosoma mansoni challenge infection in murine and nonhuman primate models.
Vaccine. 2011 Mar 9;29(12):2262-71. doi: 10.1016/j.vaccine.2011.01.040. Epub 2011 Jan 28.
9
Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic.
J Infect Dis. 2011 Nov;204(9):1437-49. doi: 10.1093/infdis/jir545. Epub 2011 Sep 15.
10
Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon.
Parasitol Res. 2014 Jun;113(6):2239-50. doi: 10.1007/s00436-014-3879-8. Epub 2014 Apr 12.
引用本文的文献
1
Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review.
PLoS Negl Trop Dis. 2025 Jun 2;19(6):e0012956. doi: 10.1371/journal.pntd.0012956. eCollection 2025 Jun.
2
Recent Advances and Methodological Considerations on Vaccine Candidates for Human Schistosomiasis.
Front Trop Dis. 2021 Aug;2. doi: 10.3389/fitd.2021.719369. Epub 2021 Aug 26.
3
Vaccines for Human Schistosomiasis: Recent Progress, New Developments and Future Prospects.
Int J Mol Sci. 2022 Feb 18;23(4):2255. doi: 10.3390/ijms23042255.
4
A comprehensive and critical overview of schistosomiasis vaccine candidates.
J Parasit Dis. 2021 Jun;45(2):557-580. doi: 10.1007/s12639-021-01387-w. Epub 2021 Apr 25.
5
Current status and future prospects of protein vaccine candidates against infection.
Parasite Epidemiol Control. 2020 Aug 20;11:e00176. doi: 10.1016/j.parepi.2020.e00176. eCollection 2020 Nov.
6
Vaccination against the digestive enzyme Cathepsin B using a YS1646 Salmonella enterica Typhimurium vector provides almost complete protection against Schistosoma mansoni challenge in a mouse model.
PLoS Negl Trop Dis. 2019 Dec 2;13(12):e0007490. doi: 10.1371/journal.pntd.0007490. eCollection 2019 Dec.
7
Molecular characterization and functional analysis of the Schistosoma mekongi Ca-dependent cysteine protease (calpain).
Parasit Vectors. 2019 Jul 30;12(1):383. doi: 10.1186/s13071-019-3639-9.
8
antigen Sm-p80: prophylactic efficacy using TLR4 agonist vaccine adjuvant glucopyranosyl lipid A-Alum in murine and non-human primate models.
J Investig Med. 2018 Dec;66(8):1124-1132. doi: 10.1136/jim-2018-000786. Epub 2018 Jul 10.
9
Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium.
Parasitol Res. 2017 Nov;116(11):3175-3188. doi: 10.1007/s00436-017-5634-4. Epub 2017 Oct 12.
10
Sm-p80-based schistosomiasis vaccine mediated epistatic interactions identified potential immune signatures for vaccine efficacy in mice and baboons.
PLoS One. 2017 Feb 13;12(2):e0171677. doi: 10.1371/journal.pone.0171677. eCollection 2017.
本文引用的文献
1
Transforming growth factor-beta and Th17 responses in resistance to primary murine schistosomiasis mansoni.
Cytokine. 2009 Dec;48(3):239-45. doi: 10.1016/j.cyto.2009.07.581. Epub 2009 Aug 29.
2
The genome of the blood fluke Schistosoma mansoni.
Nature. 2009 Jul 16;460(7253):352-8. doi: 10.1038/nature08160.
3
Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model.
Vaccine. 2009 May 11;27(21):2830-7. doi: 10.1016/j.vaccine.2009.02.096. Epub 2009 Mar 10.
4
Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis.
Vaccine. 2009 Jan 29;27(5):666-73. doi: 10.1016/j.vaccine.2008.11.039. Epub 2008 Dec 3.
5
Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection.
PLoS Negl Trop Dis. 2008 Oct 1;2(10):e308. doi: 10.1371/journal.pntd.0000308.
6
IL-1, IL-18, and IL-33 families of cytokines.
Immunol Rev. 2008 Jun;223:20-38. doi: 10.1111/j.1600-065X.2008.00624.x.
7
Induction and effector functions of T(H)17 cells.
Nature. 2008 Jun 19;453(7198):1051-7. doi: 10.1038/nature07036.
8
TH17 cells in development: an updated view of their molecular identity and genetic programming.
Nat Rev Immunol. 2008 May;8(5):337-48. doi: 10.1038/nri2295.
9
Th17 cell differentiation: the long and winding road.
Immunity. 2008 Apr;28(4):445-53. doi: 10.1016/j.immuni.2008.03.001.
10
T cells help to amplify inflammatory responses induced by Salmonella enterica serotype Typhimurium in the intestinal mucosa.
Infect Immun. 2008 May;76(5):2008-17. doi: 10.1128/IAI.01691-07. Epub 2008 Mar 17.
Zotero 插件